Epibiotech Co., Ltd. (XKON:446440)

Epibiotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3,488	3,094
Short-Term Investments	-	4,012
Cash & Short-Term Investments	3,488	7,106
Cash Growth	-50.92%	-
Accounts Receivable	10.77	61.9
Other Receivables	21.93	1.5
Receivables	32.7	63.4
Inventory	24.35	0.62
Prepaid Expenses	103.06	15.36
Other Current Assets	86.94	904.53
Total Current Assets	3,735	8,090
Property, Plant & Equipment	4,985	4,390
Other Intangible Assets	361.05	218.37
Other Long-Term Assets	215.98	185.98
Total Assets	9,297	12,884
Accrued Expenses	107.52	58.97
Short-Term Debt	523	523
Current Portion of Long-Term Debt	1,913	1,247
Other Current Liabilities	187.98	301.93
Total Current Liabilities	2,732	2,131
Long-Term Debt	199.84	933.28
Other Long-Term Liabilities	60	-
Total Liabilities	2,992	3,064
Common Stock	852.75	847.75
Additional Paid-In Capital	16,636	15,138
Retained Earnings	-11,838	-6,780
Comprehensive Income & Other	-0	-0
Total Common Equity	5,651	9,206
Shareholders' Equity	6,305	9,820
Total Liabilities & Equity	9,297	12,884
Total Debt	2,636	2,703
Net Cash (Debt)	851.49	4,403
Net Cash Growth	-80.66%	-
Net Cash Per Share	499.33	2597.53
Filing Date Shares Outstanding	1.71	1.7
Total Common Shares Outstanding	1.71	1.7
Working Capital	1,003	5,959
Book Value Per Share	3313.83	5430.64
Tangible Book Value	5,290	8,987
Tangible Book Value Per Share	3102.11	5301.82
Land	1,127	787.78
Buildings	2,367	1,631
Machinery	974.03	824.65
Construction In Progress	809.65	748.05

Source: S&P Global Market Intelligence. Standard template. Financial Sources.